Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Rasagiline Mesylate Patent Expiration

Rasagiline Mesylate is Used for managing the symptoms of Parkinson's disease. It was first introduced by Teva Neuroscience Inc in its drug Azilect on May 16, 2006. 12 different companies have introduced drugs containing Rasagiline Mesylate.


Rasagiline Mesylate Patents

Given below is the list of patents protecting Rasagiline Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Azilect US5453446 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. Feb 07, 2017

(Expired)

 Teva
Azilect US5532415 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof Jul 02, 2013

(Expired)

 Teva
Azilect US6126968 Stable compositions containing N-propargyl-1-aminoindan Sep 18, 2016

(Expired)

 Teva
Azilect US7572834 Rasagiline formulations and processes for their preparation Dec 05, 2026 Teva
Azilect US7815942 Rasagiline formulations of improved content uniformity Aug 27, 2027 Teva


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Rasagiline Mesylate Generics

Several generic applications have been filed for Rasagiline Mesylate. The first generic version for Rasagiline Mesylate was by Watson Laboratories Inc and was approved on Jul 1, 2013. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jun 28, 2024.

Given below is the list of companies who have filed for Rasagiline Mesylate generic.


1. CHARTWELL RX

Chartwell Rx Sciences Llc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Jul 27, 2018
EQ 1MG BASE tablet Prescription ORAL AB Jul 27, 2018


2. AUROBINDO PHARMA USA

Aurobindo Pharma Usa Inc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB May 15, 2017
EQ 1MG BASE tablet Prescription ORAL AB May 15, 2017


3. MICRO LABS

Micro Labs Ltd has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Micro Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Mar 29, 2019
EQ 1MG BASE tablet Prescription ORAL AB Mar 29, 2019


4. CARNEGIE

Carnegie Pharmaceuticals Llc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Carnegie.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Discontinued ORAL N/A Nov 18, 2021
EQ 1MG BASE tablet Discontinued ORAL N/A Nov 18, 2021


5. ORBION PHARMS

Orbion Pharmaceuticals Private Ltd has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Orbion Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Mar 15, 2016
EQ 1MG BASE tablet Prescription ORAL AB Mar 15, 2016


6. APOTEX INC

Apotex Inc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Apotex Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Discontinued ORAL N/A Sep 12, 2013
EQ 1MG BASE tablet Discontinued ORAL N/A Sep 12, 2013


7. SKG PHARMA

Skg Pharma Inc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Skg Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 1MG BASE tablet Prescription ORAL AB Apr 9, 2024
EQ 0.5MG BASE tablet Prescription ORAL AB Apr 9, 2024


8. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Oct 30, 2017
EQ 1MG BASE tablet Prescription ORAL AB Oct 30, 2017


9. INDOCO

Indoco Remedies Ltd has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Indoco.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Oct 4, 2019
EQ 1MG BASE tablet Prescription ORAL AB Oct 4, 2019


10. MACLEODS PHARMS LTD

Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Prescription ORAL AB Jun 28, 2024
EQ 1MG BASE tablet Prescription ORAL AB Jun 28, 2024


11. WATSON LABS INC

Watson Laboratories Inc has filed for 2 different strengths of generic version for Rasagiline Mesylate. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG BASE tablet Discontinued ORAL N/A Jul 1, 2013
EQ 1MG BASE tablet Discontinued ORAL N/A Jul 1, 2013